The GAO Report about the FDA’s Inspection Workforce: the Implications for Federal Government Contractors in Clinical Research

The Government Accountability Office (GAO) report "CLINICAL RESEARCH: FDA Should Evaluate Its Efforts to Recruit and Retain Its Inspection Workforce" (GAO-24-106383, February 2024) sheds light on critical challenges that the Food and Drug Administration (FDA) faces when overseeing clinical research. As federal government contractors, particularly those participating in clinical research or providing services linked to medication development and approval, you should understand the report's conclusions and the potential implications for your operations.

The FDA plays an important role in monitoring the quality and integrity of clinical research used to support drug marketing applications. The FDA inspects clinical research firms under its Bioresearch Monitoring (BIMO) program to protect human participants and ensure data dependability. However, the GAO study shows a considerable fall in the number of FDA clinical research inspections since fiscal year 2017, with a particularly noticeable drop during the COVID-19 epidemic. This decrease is ascribed to the pandemic's effects and staffing shortages, raising questions about the FDA's ability to maintain effective regulation of clinical trials.

In response to the obstacles created by the epidemic, the FDA began using remote regulatory assessments instead of typical on-site inspections. These exams involve tasks like evaluating documents and holding virtual meetings with site workers. Remote regulatory assessments have been useful in some cases, but they are not considered a substitute for in-person inspections. According to the GAO study, the FDA is considering continuing to employ these tools, which might have an impact on how clinical research companies prepare for and participate with regulatory monitoring.

One of the report's key conclusions is the FDA's difficulty recruiting and retaining BIMO investigators, which has contributed to the decrease in inspections. According to the GAO, low salary and considerable travel requirements have made it difficult to sustain a viable inspection crew. The FDA has taken steps to address these difficulties, such as enhanced remuneration and student loan repayment, but their effectiveness has yet to be properly assessed.

For federal government contractors participating in clinical research or drug development, the GAO report's conclusions have significant consequences.

1. Potential Delays in Drug Approval Processes: The decrease in FDA inspections and the problems of keeping appropriate personnel may cause delays in the evaluation and approval of drug marketing applications. Contractors should be prepared for regulatory timing uncertainty and plan methods to lessen the impact on their projects.

2. Adapting to Remote Oversight: As the FDA considers the continued use of remote regulatory assessments, contractors must ensure that they have the required infrastructure and standards in place to facilitate these assessments. This includes effective document sharing systems and virtual communication tools.

3. Enhanced Compliance Efforts: Given the FDA's difficulties in conducting inspections, contractors must maintain strict compliance with regulatory requirements. Proactively addressing any shortcomings and following good clinical practices might help to reduce problems during inspections or evaluations.

4. Compliance with Regulatory Developments: Contractors should be aware of the FDA's initiatives to resolve staffing concerns and any changes to inspection processes. Engaging with the agency and industry groups can give information on changing regulatory standards and best practices.

• Stay informed and interact with industry partners. Subscribe to our Newsletter and read our Blog on a regular basis to be informed about events in the field of federal government contracting.

The GAO report underscores substantial obstacles that the FDA faces when regulating clinical research, which has ramifications for federal government contractors involved in medication development and approval. Contractors can overcome these hurdles by understanding the report's findings and responding to the changing regulatory situation. Proactive steps, such as improving compliance, planning for remote evaluations, and maintaining current on regulatory developments, will be critical to successfully navigate this complex environment.

The content on this site, including articles, images, and logos, is protected by copyright and intellectual property laws and is intended for educational and informational purposes only. It should not be considered legal advice. Laws and regulations may vary by jurisdiction and are subject to change. For legal advice, consult with a qualified attorney or legal professional.

FedFeather Frank says:

“This report is important for federal government contractors, especially those involved in clinical research or providing services related to drug development and approval, as it highlights the challenges faced by the FDA in maintaining its inspection workforce and the potential impact on the regulatory oversight of clinical research. Understanding these challenges can help contractors anticipate potential delays in drug approval processes and adapt their strategies accordingly.”